JP7429455B2 - Ａｆｐ抗原を識別するｔ細胞受容体 - Google Patents
Ａｆｐ抗原を識別するｔ細胞受容体 Download PDFInfo
- Publication number
- JP7429455B2 JP7429455B2 JP2021529507A JP2021529507A JP7429455B2 JP 7429455 B2 JP7429455 B2 JP 7429455B2 JP 2021529507 A JP2021529507 A JP 2021529507A JP 2021529507 A JP2021529507 A JP 2021529507A JP 7429455 B2 JP7429455 B2 JP 7429455B2
- Authority
- JP
- Japan
- Prior art keywords
- tcr
- seq
- amino acid
- chain
- exon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091008874 T cell receptors Proteins 0.000 title claims description 342
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title claims description 317
- 102100023635 Alpha-fetoprotein Human genes 0.000 title claims description 39
- 108091007433 antigens Proteins 0.000 title claims description 38
- 102000036639 antigens Human genes 0.000 title claims description 38
- 239000000427 antigen Substances 0.000 title claims description 37
- 210000004027 cell Anatomy 0.000 claims description 97
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 78
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 57
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 57
- 235000001014 amino acid Nutrition 0.000 claims description 54
- 101000662902 Homo sapiens T cell receptor beta constant 2 Proteins 0.000 claims description 51
- 102100037298 T cell receptor beta constant 2 Human genes 0.000 claims description 51
- 101000662909 Homo sapiens T cell receptor beta constant 1 Proteins 0.000 claims description 50
- 102100037272 T cell receptor beta constant 1 Human genes 0.000 claims description 50
- 150000001413 amino acids Chemical class 0.000 claims description 46
- 150000007523 nucleic acids Chemical class 0.000 claims description 44
- 239000013598 vector Substances 0.000 claims description 44
- 239000002773 nucleotide Substances 0.000 claims description 41
- 125000003729 nucleotide group Chemical group 0.000 claims description 41
- 108020004707 nucleic acids Proteins 0.000 claims description 39
- 102000039446 nucleic acids Human genes 0.000 claims description 39
- 230000027455 binding Effects 0.000 claims description 20
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 15
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 239000003550 marker Substances 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 239000000833 heterodimer Substances 0.000 claims description 8
- 101150008942 J gene Proteins 0.000 claims description 6
- 230000002998 immunogenetic effect Effects 0.000 claims description 6
- 210000000130 stem cell Anatomy 0.000 claims description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 210000000349 chromosome Anatomy 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000030062 persistent idiopathic facial pain Diseases 0.000 description 35
- 230000009258 tissue cross reactivity Effects 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 22
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 19
- 238000000034 method Methods 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 17
- 210000003000 inclusion body Anatomy 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000012636 effector Substances 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- 239000011534 wash buffer Substances 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 230000006287 biotinylation Effects 0.000 description 4
- 238000007413 biotinylation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 3
- 229940099500 cystamine Drugs 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 239000012557 regeneration buffer Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002463 transducing effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000004960 NAD(P)H dehydrogenase (quinone) Human genes 0.000 description 2
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 101710130607 Valacyclovir hydrolase Proteins 0.000 description 2
- 102100025139 Valacyclovir hydrolase Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000385 dialysis solution Substances 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000006461 physiological response Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 1
- 101100172874 Caenorhabditis elegans sec-3 gene Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 235000000638 D-biotin Nutrition 0.000 description 1
- 239000011665 D-biotin Substances 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100096028 Mus musculus Smok1 gene Proteins 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 101100449943 Oryza sativa subsp. japonica GLU15 gene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241001112090 Pseudovirus Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 241000703392 Tribec virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000011034 membrane dialysis Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4264—Cancer antigens from embryonic or fetal origin
- A61K40/4265—Alpha-feto protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810854117.4A CN110776562B (zh) | 2018-07-30 | 2018-07-30 | 一种识别afp抗原的t细胞受体 |
| CN201810854117.4 | 2018-07-30 | ||
| PCT/CN2019/098245 WO2020024915A1 (zh) | 2018-07-30 | 2019-07-29 | 一种识别afp抗原的t细胞受体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021531834A JP2021531834A (ja) | 2021-11-25 |
| JPWO2020024915A5 JPWO2020024915A5 (https=) | 2022-08-04 |
| JP2021531834A5 JP2021531834A5 (https=) | 2022-08-04 |
| JP7429455B2 true JP7429455B2 (ja) | 2024-02-08 |
Family
ID=69232312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529507A Active JP7429455B2 (ja) | 2018-07-30 | 2019-07-29 | Ａｆｐ抗原を識別するｔ細胞受容体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12152065B2 (https=) |
| EP (1) | EP3831845A4 (https=) |
| JP (1) | JP7429455B2 (https=) |
| CN (1) | CN110776562B (https=) |
| CA (1) | CA3108466A1 (https=) |
| WO (1) | WO2020024915A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111662374B (zh) * | 2019-03-08 | 2023-01-24 | 香雪生命科学技术（广东）有限公司 | 一种识别afp抗原的高亲和力tcr |
| AU2021219334A1 (en) * | 2020-02-14 | 2022-09-01 | Adaptimmune Limited | Method of treatment of cancer or tumour |
| CN113321727B (zh) * | 2020-02-28 | 2024-04-09 | 香雪生命科学技术（广东）有限公司 | 一种识别afp抗原短肽的t细胞受体及其编码序列 |
| CN113493505A (zh) * | 2020-03-20 | 2021-10-12 | 香雪生命科学技术（广东）有限公司 | 识别afp抗原的高亲和力tcr |
| WO2022022696A1 (zh) * | 2020-07-30 | 2022-02-03 | 香雪生命科学技术（广东）有限公司 | 一种识别afp的高亲和力tcr |
| US20240279318A1 (en) * | 2021-05-31 | 2024-08-22 | Nanjing Legend Biotech Co., Ltd. | Antibodies targeting afp peptide/mhc complexes and uses thereof |
| JP7210677B1 (ja) * | 2021-10-20 | 2023-01-23 | デンカ株式会社 | 非水硬性セメント組成物及びセメント系材料 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104087592A (zh) | 2014-05-13 | 2014-10-08 | 天津医科大学总医院 | Afp158-166特异性tcr基因及其转基因t细胞及体外增殖方法及用途 |
| JP2016523268A (ja) | 2013-06-26 | 2016-08-08 | グアンツォウ シャンスエ ファーマシューティカル カンパニー リミテッドＧｕａｎｇｚｈｏｕ Ｘｉａｎｇｘｕｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ． Ｌｔｄ | 高安定性のｔ細胞受容体およびその製法と使用 |
| JP2016525537A (ja) | 2013-07-26 | 2016-08-25 | アダプティミューネ リミテッドＡｄａｐｔｉｍｍｕｎｅ Ｌｉｍｉｔｅｄ | Ｔ細胞レセプター |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016243026B2 (en) * | 2015-04-03 | 2022-03-31 | Eureka Therapeutics, Inc. | Constructs targeting AFP peptide/MHC complexes and uses thereof |
| CN107847570A (zh) * | 2015-05-08 | 2018-03-27 | 优瑞科生物技术公司 | 靶向hpv16‑e7肽/mhc复合体的构建体及其用途 |
| CN107922471A (zh) * | 2015-06-24 | 2018-04-17 | 优瑞科生物技术公司 | 靶向ny‑eso‑1肽/mhc复合物的构建体及其用途 |
| GB201520575D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| CN105524884A (zh) * | 2016-02-29 | 2016-04-27 | 时宏珍 | Hla-a0201限制性抗afp抗原特异性ctl的制备方法 |
| SG11201909751TA (en) * | 2017-05-12 | 2019-11-28 | Augusta University Research Institute Inc | Human alpha fetoprotein-specific t cell receptors and uses thereof |
| CN111662374B (zh) * | 2019-03-08 | 2023-01-24 | 香雪生命科学技术（广东）有限公司 | 一种识别afp抗原的高亲和力tcr |
-
2018
- 2018-07-30 CN CN201810854117.4A patent/CN110776562B/zh active Active
-
2019
- 2019-07-29 EP EP19845331.8A patent/EP3831845A4/en not_active Withdrawn
- 2019-07-29 WO PCT/CN2019/098245 patent/WO2020024915A1/zh not_active Ceased
- 2019-07-29 JP JP2021529507A patent/JP7429455B2/ja active Active
- 2019-07-29 US US17/264,649 patent/US12152065B2/en active Active
- 2019-07-29 CA CA3108466A patent/CA3108466A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016523268A (ja) | 2013-06-26 | 2016-08-08 | グアンツォウ シャンスエ ファーマシューティカル カンパニー リミテッドＧｕａｎｇｚｈｏｕ Ｘｉａｎｇｘｕｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ． Ｌｔｄ | 高安定性のｔ細胞受容体およびその製法と使用 |
| JP2016525537A (ja) | 2013-07-26 | 2016-08-25 | アダプティミューネ リミテッドＡｄａｐｔｉｍｍｕｎｅ Ｌｉｍｉｔｅｄ | Ｔ細胞レセプター |
| CN104087592A (zh) | 2014-05-13 | 2014-10-08 | 天津医科大学总医院 | Afp158-166特异性tcr基因及其转基因t细胞及体外增殖方法及用途 |
Non-Patent Citations (2)
| Title |
|---|
| BUTTERFIELD LH. et al.，T Cell Responses to HLA-A*0201-Restricted Peptides Derived from Human a Fetoprotein，J Immunol, 2001, vol. 166, p. 5300-5308 |
| SUN L. et al.，Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma，Tumor Biol, 2016, vol. 37, p. 799-806 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3831845A4 (en) | 2022-05-04 |
| CA3108466A1 (en) | 2020-02-06 |
| JP2021531834A (ja) | 2021-11-25 |
| EP3831845A1 (en) | 2021-06-09 |
| CN110776562B (zh) | 2022-06-17 |
| US20210324034A1 (en) | 2021-10-21 |
| CN110776562A (zh) | 2020-02-11 |
| US12152065B2 (en) | 2024-11-26 |
| WO2020024915A1 (zh) | 2020-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7452880B2 (ja) | Ｓｓｘ２抗原を識別するｔ細胞受容体 | |
| JP7556583B2 (ja) | Ｋｒａｓ突然変異を識別するｔ細胞受容体およびそのコード配列 | |
| JP7429455B2 (ja) | Ａｆｐ抗原を識別するｔ細胞受容体 | |
| CN106632660B (zh) | 识别ny-eso-1抗原短肽的tcr | |
| CN110343166B (zh) | 识别afp抗原短肽的t细胞受体 | |
| CN109575121B (zh) | 识别afp抗原短肽的t细胞受体 | |
| CN110343167B (zh) | 识别ssx2抗原短肽的t细胞受体 | |
| CN110577591B (zh) | 一种识别afp抗原短肽的t细胞受体及其编码序列 | |
| CN106478808B (zh) | 识别ny-eso-1抗原短肽的t细胞受体 | |
| CN106336457B (zh) | 识别mage‑a3抗原短肽的t细胞受体 | |
| WO2021022447A1 (zh) | 识别afp抗原短肽的t细胞受体 | |
| JP7429462B2 (ja) | Ｓｓｘ２抗原の短いペプチドを識別するｔ細胞受容体 | |
| TW202140539A (zh) | 一種辨識ａｆｐ抗原短鏈胜肽的ｔ細胞受體及其編碼序列 | |
| CN113072636B (zh) | 一种识别afp的t细胞受体及其编码序列 | |
| WO2021170116A1 (zh) | 一种识别afp的t细胞受体 | |
| CN110407927B (zh) | 一种识别afp抗原的tcr | |
| CN109400696B (zh) | 一种识别prame抗原短肽的tcr | |
| CN108948184B (zh) | 一种识别衍生自prame抗原短肽的t细胞受体 | |
| CN110627894B (zh) | 识别ny-eso-1抗原短肽的t细胞受体及其编码序列 | |
| CN110577590B (zh) | 一种识别afp抗原的tcr及其编码核酸 | |
| CN109575120B (zh) | 识别prame抗原短肽的tcr及其编码序列 | |
| CN110407926B (zh) | 一种识别lmp1抗原短肽的tcr及其编码序列 | |
| WO2022206861A1 (zh) | 识别afp的t细胞受体 | |
| WO2021035446A1 (zh) | 一种识别afp抗原短肽的t细胞受体及其编码序列 | |
| CN115490767A (zh) | 一种识别afp抗原的tcr及其编码序列 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20210422 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210422 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220727 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220727 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230613 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230614 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230913 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231110 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231213 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231222 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240122 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7429455 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |